Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how well eczema drug works in real life for 1,000 patients in china

NCT ID NCT06421740

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study will follow about 1,000 adolescents and adults in China who are prescribed upadacitinib for moderate to severe atopic dermatitis (eczema). Researchers will track how patients use the medication, any dose changes, and how well they stick to their treatment over 12 months. The goal is to see how the drug performs in real-world settings, outside of a controlled clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upadacitinib (oral tablet)
What this could lead to
If successful, this study could show how well upadacitinib works in everyday practice for people with atopic dermatitis in China.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. It also only follows patients for 12 months, so long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

Jun 2024

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adolescent and adult Chinese participants with atopic dermatitis (AD) who are prescribed Upadacitinib by their physician according to their local label.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adolescents (body weight \>= 40 kg at the Baseline Visit for patients between \>= 12 and \< 18 years of age) and adults at the time of enrollment. * Clinical diagnosis of moderate to severe atopic dermatitis at the time of enrollment. * UPA treatment is indicated for AD and prescribed as per Chinese label / SmPC. * The decision to prescribe UPA is made prior to and independent of study participation. * The participant should not be treated with UPA prior to this study. * Participants who are willing and able to participate in the collection of patient-reported data, including ePROs and eDiary via apps. * The participant (legal representative for adolescents) voluntarily signed an informed consent before any study-related activities are conducted. Exclusion Criteria: * The participant is currently participating in interventional research (not including noninterventional study, observational study, or registry participation). * Any circumstances that the investigator believes may limit the patient's participation and compliance with study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Affiliated Hospital Of Nantong University /ID# 269743

    Nantong, Jiangsu, 226001, China

  • Beijing Anzhen Hospital /ID# 273443

    Beijing, Beijing Municipality, 100029, China

  • Changgeng Hospital /ID# 268209

    Xiamen, Fujian, 361022, China

  • China-Japan Friendship Hospital /ID# 274778

    Beijing, Beijing Municipality, 100029, China

  • Dalian Dermatosis Hospital /ID# 272495

    Dalian, Liaoning, 116041, China

  • Guangzhou Dermatology Hospital /ID# 271684

    Guangzhou, Guangdong, 510095, China

  • Hainan Fifth People's Hospital /ID# 269747

    Hainan, Hainan, 200000, China

  • Hebei Engineering University Affiliated Hospital /ID# 268660

    Handan, Hebei, 200000, China

  • Huashan Hospital Of Fudan University /ID# 270277

    Shanghai, Shanghai Municipality, 200040, China

  • Jining Medical University - Affiliated Hospital /ID# 270873

    Jining, Shandong, 272029, China

  • Nanjing Drum Tower Hospital /ID# 268616

    Nanjing, Jiangsu, 210008, China

  • Ningbo No.6 hospital /ID# 268315

    Ningbo, Zhejiang, 315040, China

  • Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 264193

    Beijing, Beijing Municipality, 100730, China

  • Peking University First Hospital /ID# 274865

    Beijing, Beijing Municipality, 100034, China

  • Peking Unversity Third hospital /ID# 274864

    Beijing, Beijing Municipality, 100191, China

  • People's Hospital of Henan Province /ID# 269744

    Zhengzhou, Henan, 450003, China

  • People's Hospital of Xinjiang Uygur Autonomous Region /ID# 269746

    Ürümqi, Xinjiang, 830001, China

  • Ruijin Hospital /ID# 268658

    Shanghai, Shanghai Municipality, 200025, China

  • Shandong Provincial Hospital /ID# 268661

    Jinan, Shandong, 250001, China

  • Shanghai Sixth People'S Hospital /ID# 268617

    Shanghai, Shanghai Municipality, 200233, China

  • Shanghai Skin Disease Hospital /ID# 268657

    Shanghai, Shanghai Municipality, 200443, China

  • Sichuan Provincial People's Hospital /ID# 268314

    Chengdu, Sichuan, 610072, China

  • Taizhou Central Hospital /ID# 268211

    Taizhou, Zhejiang, 318000, China

  • The Affiliated Hospital Of Southwest Medical University /ID# 268207

    Luzhou, Sichuan, 646600, China

  • The Affiliated Hospital of Xuzhou Medical College /ID# 268208

    Xuzhou, Jiangsu, 221006, China

  • The Fifth Affiliated Hospital Of Sun Yat-Sen University /ID# 268618

    Zhuhai, Guangdong, 519000, China

  • The First Affiliated Hospital Of Fujian Medical University /ID# 268210

    Fuzhou, Fujian, 350005, China

  • The First Affiliated Hospital of Kunming Medical College /ID# 273451

    Kunming, Yunnan, 650032, China

  • The First Affiliated Hospital of Soochow University /ID# 269742

    Suzhou, Jiangsu, 215006, China

  • The People's Hospital of Liaoning Province /ID# 268206

    Shenyang, Liaoning, 110016, China

  • The Second Affiliated Hospital Of Harbin Medical University /ID# 270872

    Harbin, Heilongjiang, 150001, China

  • Tongji Hospital /ID# 269745

    Wuhan, Hubei, 430030, China

  • Weifang People'S Hospital /ID# 268659

    Weifang, Shandong, 261041, China

  • West China Hospital of Sichuan University /ID# 268313

    Chengdu, Sichuan, 610041, China

  • Wuhan Integrated TCM & Western Medicine Hospital（Wuhan No.1 Hospital) /ID# 272374

    Wuhan, Hubei, 430022, China

  • Xiangya Hospital Central South University /ID# 272373

    Changsha, Hunan, 410008, China

  • Zhejiang Provincial Hospital of Chinese Medicine /ID# 268613

    Hangzhou, Zhejiang, 310006, China

  • Zhuji People'S Hospital /ID# 268614

    Zhuji, Zhejiang, 315000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.